共 50 条
- [31] Magnetic resonance imaging results from the first year of the ADVANCE study, a pivotal phase 3 trial of peginterferon β-1a in patients with relapsing-remitting multiple sclerosis[J]. MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 452 - 453Arnold, D.Calabresi, P.Kieseier, B.Zhu, Y.Liu, S.Hung, S.Deykin, A.Sheikh, S.
- [32] A RANDOMIZED PHASE 3 STUDY OF ALLOGENEIC HCT WITH IOMAB-B VERSUS CONVENTIONAL CARE IN OLDER PATIENTS WITH ACTIVE, RELAPSED/REFRACTORY AML: PIVOTAL SIERRA TRIAL RESULTS[J]. BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 50 - 52Giralt, SergioGyurkocza, BoglarkaSeropian, StuartChoe, HannahLitzow, MarkAbboud, CamilleKoshy, NebuStiff, PatrickTomlinson, BenjaminAbhyankar, SunilForan, JamesHari, ParameswaranChen, GeorgeAl-Kadhimi, ZaidKebriaei, PartowSabloff, MitchellOrozco, JohnnieJamieson, KatarzynaMagalhaes-Silverman, MargaridaVan Besien, KoenSchuster, MichaelLaw, ArjunAbedin, SameemLarkin, KarilynRowley, ScottMunshi, PashnaCook, RachelMayer, SebastianLevy, Moshe YairLazarus, HillardSandmaier, BrendaReddy, VijaySpross, JenniferMcNamara, KathleenHaeuber, ElainaNahar, AkashPagel, JohnDesai, AvinashNath, Rajneesh
- [33] LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH COLCHICINE-RESISTANT FMF (CRFMF), TRAPS AND HIDS/MKD: RESULTS FROM THE PIVOTAL PHASE 3 CLUSTER TRIAL[J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 486 - 487De Benedetti, F.Frenkel, J.Simon, A.Anton, J.Lachmann, H.Gattorno, M.Ozen, S.Kone-Paut, I.Ben-Chetrit, E.Wozniak, M. B.Wang, J. G.Vritzali, E.
- [34] Long-Term Efficacy and Safety of Canakinumab in Patients with Colchicine-Resistant FMF (crFMF), Hids/Mkd and TRAPS: Results from the Pivotal Phase 3 Cluster Trial[J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70De Benedetti, FabrizioFrenkel, JoostSimon, AnnaAnton, JordiLachmann, Helen J.Gattorno, MarcoOzen, SezaKone-Paut, IsabelleBen-Chetrit, EldadWozniak, MagdalenaWei, XiaolingVritzali, Eleni
- [35] Efficacy and safety of PXT3003 in patients with Charcot-Marie-Tooth type 1A: Results of PLEO-CMT, an international pivotal phase 3 trial[J]. NEUROLOGY, 2019, 93 (05) : E530 - E530Thomas, Florian P.Boutalbi, YoucefFitoussi, SergeRinaudo, PhilippeBertrand, VivianeHajj, RodolpheNabirotchkin, SergueiCohen, Daniel H.
- [36] External Validation of the Autoinflammatory Disease Activity Index (AIDAI) in Patients with Colchicine-Resistant FMF, Hids/Mkd, and TRAPS: Results from a Pivotal, Phase 3 Trial of Canakinumab[J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70Kone-Paut, IsabellePiram, MaryamBenseler, SusanneKuemmerle-Deschner, Jasmin B.Jansson, Annette F.Rosner, ItzhakTommasini, AlbertoMurias, SaraKaradag, OmerLevy, JeremySmeets, SergeDe Benedetti, Fabrizio
- [37] Efficacy and Safety of Biosimilar QL1207 vs. the Reference Aflibercept for Patients with Neovascular Age-Related Macular Degeneration: A Randomized Phase 3 Trial[J]. Ophthalmology and Therapy, 2024, 13 : 353 - 366Bing LiKe FanTonghe ZhangZhifeng WuSiming ZengMingwei ZhaoQian RenDongping ZhengLifei WangXiaoling LiuMei HanYanping SongJian YeCheng PeiJinglin YiXian WangHui PengHong ZhangZhanyu ZhouXiaoling LiangFangliang YuMiaoqin WuChaopeng LiChunling LeiJilong HaoLuosheng TangHuiping YuanShanjun CaiQiuming LiJingxiang ZhongSuyan LiLin LiuMin KeJing WangHui WangMengli ZhuZenghua WangYang YanFeng WangYouxin Chen
- [38] A PHASE 3, NON-INFERIORITY RANDOMIZED CONTROLLED TRIAL WITH FEXUPRAZAN, A NOVEL POTASSIUM-COMPETITIVE ACID BLOCKER VS. ESOMEPRAZOLE IN PATIENTS WITH EROSIVE ESOPHAGITIS[J]. GASTROENTEROLOGY, 2020, 158 (06) : S1072 - S1072Lee, Oh-YoungChun, Hoon JaiKim, Jae JunKim, Jin IlKim, Sung KookLee, Sang WooPark, Kyung SikLee, Kook LaeChoi, Suck CheiJang, Jae-Young
- [39] Efficacy and Safety of Biosimilar QL1207 vs. the Reference Aflibercept for Patients with Neovascular Age-Related Macular Degeneration: A Randomized Phase 3 Trial[J]. OPHTHALMOLOGY AND THERAPY, 2024, 13 (01) : 353 - 366Li, BingFan, KeZhang, TongheWu, ZhifengZeng, SimingZhao, MingweiRen, QianZheng, DongpingWang, LifeiLiu, XiaolingHan, MeiSong, YanpingYe, JianPei, ChengYi, JinglinWang, XianPeng, HuiZhang, HongZhou, ZhanyuLiang, XiaolingYu, FangliangWu, MiaoqinLi, ChaopengLei, ChunlingHao, JilongTang, LuoshengYuan, HuipingCai, ShanjunLi, QiumingZhong, JingxiangLi, SuyanLiu, LinKe, MinWang, JingWang, HuiZhu, MengliWang, ZenghuaYan, YangWang, FengChen, Youxin
- [40] Phase III trial of 24 weeks vs. 48 weeks capecitabine adjuvant chemotherapy for patients with stage III colon cancer: Final results of JFMC37-0801[J]. ANNALS OF ONCOLOGY, 2016, 27Yamaguchi, S.Kunieda, K.Sato, T.Naramoto, Y.Kobayashi, M.Ogata, Y.Furuhata, T.Takii, Y.Kusunoki, M.Maehara, Y.Koda, K.Okuno, K.Ohno, M.Mishima, H.Sadahiro, S.Hamada, C.Sakamoto, J.Saji, S.Tomita, N.